Gradient Investments LLC reduced its holdings in AbbVie Inc. by 7.4% in Q4, selling 5,726 shares worth about $16.3 million. Other funds like Brighton Jones and Revolve Wealth Partners increased their positions, reflecting mixed investor sentiment. AbbVie reported strong quarterly earnings beating estimates and raised its EPS guidance for 2026, but faces competitive pressures from new drugs and generic entrants. The company also declared a dividend with a 3.4% yield. Recent insider sales and varied analyst price targets highlight cautious optimism about AbbVie's near-term growth prospects.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
